Magnevist® Injection Enhanced MRA at Two Dose Levels Compared to Non Contrast MRA for the Detection of Structural Abnormalities of the Infrarenal Aorta and Peripheral Arteries

NCT00185276 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

365

Enrollment

INDUSTRY

Sponsor class

Conditions

Peripheral Vascular Disease

Interventions

DRUG: Gadopentetate dimeglumine (Magnevist, BAY86-4882)
DRUG: Gadopentetate dimeglumine (Magnevist, BAY86-4882)

Sponsor

Bayer